SCHEMBL30173271

SCHEMBL30173271

Clc1c(-c2cc3ccccc3o2)cnc2[nH]ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 2/20 0.47
CCNT1 O60563 1/20 0.45
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
CDK9 P50750 1/20 0.45
AXL P30530 1/20 0.44
PRKCI P41743 1/20 0.44
PDE4D Q08499 1/20 0.44
PRKCQ Q04759 1/20 0.42
PRKCD Q05655 1/20 0.42
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
METAP2 P50579 1/20 0.41
MKNK1 Q9BUB5 1/20 0.40
CSF1R P07333 1/20 0.40
CCNC P24863 1/20 0.40
FLT3 P36888 1/20 0.40
CDK8 P49336 1/20 0.40
LRRK2 Q5S007 1/20 0.40
NPC1 O15118 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28596888 1.00 ADRA2A (0.47) ADRA2ACCNT1CCNA2CDK2CDK9
SCHEMBL10125107 0.82 ADRA2A (0.47) ADRA2ACCNT1CCNA2CDK2CDK9
SCHEMBL414693 0.80 CDK9 (0.54) ADRA2ACCNT1CCNA2CDK2CDK9
SCHEMBL30173274 0.76 JAK1 (0.55) ADRA2APRKCQPRKCDMKNK1NPC1
SCHEMBL28597935 0.76 JAK1 (0.55) ADRA2APRKCQPRKCDMKNK1NPC1
SCHEMBL30173290 0.75 PRKCI (0.51) CDK9AXLPRKCIPRKCQCSF1R
SCHEMBL28603791 0.75 PRKCI (0.51) CDK9AXLPRKCIPRKCQCSF1R
SCHEMBL30173305 0.73 JAK2 (0.58) CDK2CDK9AXLPRKCIPRKCQ
SCHEMBL3725709 0.73 JAK2 (0.58) CDK2CDK9AXLPRKCIPRKCQ
SCHEMBL13201329 0.73 CDK8 (0.59) ADRA2ACCNT1CCNA2CDK2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113200983-B Compound with pyrrolopyridine structure, preparation method and medical application 中国药科大学 2023-01-03 CN disclosed